“I’m excited to share with you all that our review is officially out on American Chemical Society as part of the special issue “New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science”.
PROTAC technology has had an impressive impact on targeted protein degradation, but its application on integral membrane proteins is still in its beginnings. In our work we discuss the potential reasons and the latest advancements!
This is my first ever publication and it’s been such a great journey!
Extremely grateful to my whole team for the immense support.
Thanks to EndoConnect and AstraZeneca for making this possible.” – Camilla Ruffilli
Use this link to view the paper: Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation – EndoConnect